Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Andros Pharmaceuticals Co's PB Ratio or its related term are showing as below:
ROCO:6917'
s PB Ratio Range Over the Past 10 Years
Min: 1.53 Med: 2.29 Max: 5.08
Current: 3.7
During the past 7 years, Andros Pharmaceuticals Co's highest PB Ratio was 5.08. The lowest was 1.53. And the median was 2.29.
ROCO:6917's PB Ratio is ranked worse than 61.04% of 1227
companies
in the Biotechnology industry
Industry Median: 2.82
vs ROCO:6917: 3.70
During the past 12 months, Andros Pharmaceuticals Co's average Book Value Per Share Growth Rate was 9.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 8.30% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 40.20% per year.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Andros Pharmaceuticals Co was 67.80% per year. The lowest was 8.30% per year. And the median was 46.30% per year.
Back to Basics: PB Ratio
Andros Pharmaceuticals Co (ROCO:6917) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Andros Pharmaceuticals Co PB Ratio Related Terms
Andros Pharmaceuticals Co PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6917 vs VRTX, REGN, ALNY: PB Ratio Comparison
For the Biotechnology subindustry, Andros Pharmaceuticals Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Andros Pharmaceuticals Co PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Andros Pharmaceuticals Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Andros Pharmaceuticals Co's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Andros Pharmaceuticals Co (ROCO:6917) has a PB Ratio of 3.70 as of Jul. 18, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Andros Pharmaceuticals Co and its competitors. This is 62% above median its historical median of 2.29. Over the past decade, Andros Pharmaceuticals Co's PB Ratio has ranged from 1.53 to 5.08. According to the industry distribution chart, Andros Pharmaceuticals Co ranks #749 out of 1227 companies in the Biotechnology industry, placing it in the top 61%.
Is Andros Pharmaceuticals Co's PB Ratio too high?
Andros Pharmaceuticals Co's current PB Ratio of 3.70 is 62% above median its 10-year median of 2.29. Over the past 10 years, this metric has ranged from a low of 1.53 to a high of 5.08. The Biotechnology industry median PB Ratio is 2.82. Andros Pharmaceuticals Co's value of 3.70 is 31.2% above this industry median. Based on the distribution chart, Andros Pharmaceuticals Co ranks #749 out of 1227 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Andros Pharmaceuticals Co has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Andros Pharmaceuticals Co's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Andros Pharmaceuticals Co ranks #749 out of 1227 companies for PB Ratio. This places Andros Pharmaceuticals Co in the lower half of its industry. The industry median PB Ratio is 2.82. Andros Pharmaceuticals Co's value of 3.70 is 31.2% above this benchmark. Historically, Andros Pharmaceuticals Co's own PB Ratio has ranged from 1.53 to 5.08 over the past decade. While the company's 10-year median is 2.29 vs. the industry median of 2.82, Andros Pharmaceuticals Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.82, based on 1,227 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Andros Pharmaceuticals Co's current PB Ratio of 3.70 is 31.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Andros Pharmaceuticals Co and its competitors. For the Biotechnology industry, the median PB Ratio is 2.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Andros Pharmaceuticals Co's current PB Ratio is 3.70, which is 62% above median its own 10-year median of 2.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Andros Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Andros Pharmaceuticals Co (ROCO:6917) is currently considered Possible Value Trap. The stock's GF Value™ is NT$165.02, compared to a current price of NT$34.50 — trading 79.1% below its estimated fair value. The current PB Ratio is 3.70, which is 62% above median its 10-year median of 2.29 and 31.2% above the Biotechnology industry median of 2.82. Andros Pharmaceuticals Co's overall GF Score™ is 41/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Andros Pharmaceuticals Co (ROCO:6917), the current PB Ratio is 3.70 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Andros Pharmaceuticals Co (ROCO:6917) Overvalued in 2026?
Based on GuruFocus' analysis, Andros Pharmaceuticals Co stock appears to be undervalued.
The current stock price of NT$34.50 is trading 79.1% below its estimated GF Value™ of NT$165.02.
GuruFocus considers Andros Pharmaceuticals Co to be Possible Value Trap.
Key valuation signals for ROCO:6917:
PB Ratio: 3.70 (62% above median its 10-year median of 2.29)
GF Value™: NT$165.02 vs. price of NT$34.50 (79.1% below fair value)
Industry Position: 31.2% above the Biotechnology median (#749 of 1227)
No single metric tells the full story. See the ROCO:6917 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Andros Pharmaceuticals Co Ltd is a biopharmaceutical company engaged in developing novel drug delivery platform technologies. The firm focuses on the development of topical new dosage forms and non-viral gene delivery systems, with the current pipeline indicated for pain management, DNA repair, and gene therapy. Its product line comprises New Dosage Forms (Topical), Super Generics (Topical), High-End Cosmetic Ingredients (Topical), and Gene Delivery Systems (Injectable).
41GF Score
Get the complete analysis for ROCO:6917
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6917 has been successfully added to your 
